How auranofin affects leptin levels and insulin sensitivity in obesity
Official title: Molecular regulation of leptin bioavailability
Funded at Baylor College of Medicine · NIH-11059049 · Data updated 2026-11-12
This study is looking at how the drug auranofin might help people with obesity and type 2 diabetes by improving their insulin sensitivity and leptin levels, which could lead to better ways to manage their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 20, 2024 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $642,578 |
| NIH project number | 5R01DK138018-02 |
| Project ID | NIH-11059049 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with obesity and type 2 diabetes who have not responded well to lifestyle modifications.
✕Less likely to help
Patients who are not obese or do not have type 2 diabetes may not receive any benefit from this research.
What this research studies
This research investigates the effects of the FDA-approved drug auranofin on leptin levels and insulin sensitivity in individuals with obesity and type 2 diabetes. The study aims to understand how auranofin can restore normal functions in fat cells that are resistant to insulin, which is crucial for managing obesity-related health issues. By examining the drug's impact on beta-adrenergic receptors and leptin production, the research seeks to identify new treatment strategies that could improve metabolic health. Patients may benefit from insights into how existing medications can be repurposed for better management of their conditions.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve insulin sensitivity and metabolic health for patients with obesity and type 2 diabetes.
How similar studies have gone: Previous research has shown promising results with the use of auranofin in preclinical models, suggesting potential for success in this area.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Hartig, Sean — Baylor College of Medicine
- Study coordinator: Hartig, Sean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.